Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-23-112580
Filing Date
2023-10-30
Accepted
2023-10-30 16:15:28
Documents
1
Group Members
GARY RIESCHELMARK MCDADEQIMING U.S. HEALTHCARE FUND II, L.P.QIMING U.S. HEALTHCARE FUND III, L.P.QIMING U.S. HEALTHCARE FUND, L.P.QIMING U.S. HEALTHCARE GP III, LLCQIMING U.S. HEALTHCARE GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm2329269d1_sc13da.htm SC 13D/A 188018
  Complete submission text file 0001104659-23-112580.txt   189947
Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Subject) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92543 | Film No.: 231360417
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 11100 NE 8TH ST, SUITE 200 BELLEVUE WA 98004
Business Address 11100 NE 8TH ST, SUITE 200 BELLEVUE WA 98004 425-709-0772
Qiming U.S. Healthcare GP II, LLC (Filed by) CIK: 0001868862 (see all company filings)

EIN.: 833293758 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A